A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro
Research payments
$1,423,506
Through program year 2020, $1,423,506 in research payments was reported against A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro, across 360 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $1,600 | 3 |
| 2019 | Research | $1,421,906 | 357 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Lawrence Sher Rolling Hills Estates, CA Named on 15 payments
- Barbara Baxter Dallas, TX Named on 12 payments
- Ricardo Tan Los Angeles, CA Named on 9 payments
- David Marks San Antonio, TX Named on 8 payments
- Alan Goldsobel San Jose, CA Named on 8 payments
- Charles Humphries Matthews, NC Named on 8 payments
- Wendy Moore Winston Salem, NC Named on 7 payments
- Robert Chrzanowski Columbus, GA Named on 7 payments
- Martha Tarpay Oklahoma City, OK Named on 6 payments
- Edward Kerwin Medford, OR Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.